Document is current
Any future updates will be listed below
-
Authors
Sharma, Ashish https://orcid.org/0000-0002-8550-9791
Woo, Se Joon https://orcid.org/0000-0003-3692-7169
Lee, Christopher Seungkyu
Kumar, Nilesh https://orcid.org/0000-0002-7439-2081
Parachuri, Nikulaa
Bandello, Francesco https://orcid.org/0000-0003-3238-9682
Loewenstein, Anat https://orcid.org/0000-0002-7706-1165
Kuppermann, Baruch D.
- License Information
-
More Information
Article History
Received: 30 January 2025
Revised: 12 February 2025
Accepted: 13 February 2025
First Online: 19 February 2025
Competing interests
: AS: CONSULTANT: for Novartis, Allergan, Bayer and Intas. SJW: received consulting fees from Samsung Bioepis, Curacle, Novelty Nobility, Pharmabcine, Sometech, Samil, Allergan, Janssen; lecture fees from Bayer, Navartis, Allergan/Abbvie, Santen, Samil; grants from Samsung Bioepis, Alcon, Alteogen, Curacle, Kyowa Kirin, Novelty Nobility, Novartis, Pharmabcine, Roche; owns equity of RetiMark and Panolos Bioscience. CSL: CLINICAL TRIALS: Bayer, Roche, Novartis, Pharmabcin, Alteogen, Kyowa Kirin; CONSULTING FEES: Eyegene, Allergan/Abbvie, Santen, Curacle, Pharmabcin, Samil, Chong Kun Dang; LECTURE FEES: Bayer, Novartis, Allergan/Abbvie, Roche, Santen, Samil, Kukje. NK: None. NP: None. Dr Francesco Bandello: CONSULTANT: Allergan, Bayer, Boehringer- Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. AL reports other from Allergan, other from Novartis, other from Roche, other from Notal Vision, other from Forsightslabs, other from Beyeonics, other from Bayer Health Care. BDK: CLINICAL RESEARCH: Adverum, Alimera, Allegro, Allergan, Apellis, Astellas, Boehringer Ingelheim, Clearside, EyePoint, 4DMT, Genentech, GSK, Ionis, IvericBio, jCyte, Novartis, Regeneron CONSULTANT: AbbVie, Adverum, Alimera, Alkeus, Allegro,, Apellis, Astellas, Eyebio, Eyedaptic, EyePoint, ForVision, Galimedix, Genentech, Glaukos, Inflammx, Interface Biologics/Ripple Therapeutics, jCyte, Novartis, Ocular Therapeutix, Oculis, OphtiMedRx, Outlook Therapeutics, Regeneron, Revana, Theravance Biopharma, VisgenX.
